Bausch + Lomb Receives FDA Approval of Lumify Preservative Free Eye Drops
Bausch + Lomb Corporation announced that the U.S. Food and Drug Administration (FDA) has approved Lumify Preservative Free redness reliever eye drops and over-the-counter brimonidine tartrate for the treatment of ocular redness due to minor eye irritations. According to the company, Lumify Preservative Free contains a unique formulation and selectively targets redness, similar to Lumify.
CLI Data Illustrates Significant Upside Opportunity for Eyecare Practices
The Contact Lens Institute (CLI) has published an in-depth report on everyday actions that the eyecare community can take to draw interest from potential and former contact lens wearers. Based on research with more than 1,000 vision-corrected adults segmented by glasses-only wearers, new contact lens wearers, and contact lens dropouts, “Beyond Vision: Behaviors to Attract New & Returning Contact Lens Wearers” is the latest offering from CLI’s See Tomorrow initiative, which helps practices thrive using exclusive consumer data and insights.
The 26-page document includes multiple infographics depicting takeaways ideal for staff training. Another 19 quick-take columns and bulleted checklists offer practical implementation tips, all of which were contributed by 2024 CLI Visionaries.
The research was commissioned by CLI and conducted by Prodege from Feb. 1-9 via an online survey. Respondents included 1,053 vision-corrected adults ages 18 to 64 residing in the U.S.
What Do You Want to See in Contact Lens Spectrum?
Each year, we survey our readership to solicit ideas for columns, articles, and continuing education and it is that time of year again! We really value your input as we get our most creative (and desired) content from each of you. We ask that you please take a few moments to complete the survey found here and thank you very much for your feedback.
Toku Inc. Secures FDA Breakthrough Designation for MyKidneyAI Technology
Toku Inc. announced that the FDA has granted Breakthrough Device designation to its MyKidneyAI technology. MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease (CKD) risk in people with diabetes. Most people with diabetes are not routinely screened for CKD today, resulting in the disease not being detected until it has developed to an advanced stage where straightforward interventions are no longer effective. Toku is working closely with its strategic investors, Topcon Healthcare and National Vision to provide MyKidneyAI in the U.S. market.
Glaukos’ Focus on Keratoconus Awareness Honored with a Stevie Award
Glaukos announced it has been honored with a Stevie Award for Marketing Campaign of the Year for its multifaceted keratoconus (KC) consumer awareness campaign.
The bronze level distinction from the American Business Association recognizes the consumer awareness focus of the campaign, created with agency partner PrecisionEffect, centered around the www.livingwithkeratoconus.com website and supported by social media and collateral materials breaking down KC signs and symptoms, risks, and possible rapid progression. Key calls to action include an online, downloadable quiz and a Find a Doc” webpage to make an appointment to be screened.
CAO Releases a New “GetEyeWise” Digital Campaign
The Canadian Association of Optometrists (CAO) released a digital national campaign to raise public awareness about eye health and vision care, encouraging Canadians to get their eyes checked. Several provincial associations of optometrists (New Brunswick Association of Optometrists, Newfoundland & Labrador Association of Optometrists, Nova Scotia Association of Optometrists, and The Prince Edward Island Association of Optometrists) and sponsors from the industry (Alcon, CooperVision, and Sun Pharma) joined and supported this campaign. To find more about the CAO campaign, visit opto.ca/geteyewise.